

...at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients. The Company has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases and gene therapy. Hansa Biopharma is based in Lund, Sweden with operations in Europe and in the U.S.

E(ab')

Imlifidase – A novel approach to eliminating pathogenic IgG



Origins from a bacteria Streptococcus pyogenes

- Species of Gram-positive, spherical bacteria in the genus Streptococcus
- Usually known from causing a strep throat infection

Strategic Priorities



Commercialize Idefirix® in first indications and markets

- Successfully launch Idefirix® in Europe
- Secure FDA approval and launch Idefirix® in the U.S.
- Geographical expansion

Achieved and Upcoming Milestones

Imlifidase, a unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
 - Cleaves IgG at the hinge region, generating one F(ab')2 fragment and one homo-dimeric Fc-fragment



Imlifidase inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



Expand IgG-cleaving enzyme technology platform into new disease areas and indications

- Explore gene therapy
- Explore opportunities in Oncology and stem cell
- Develop our next generation IgG-cleaving enzymes to allow for recurring treatment

Q4 2023 HNSA-6487 (Lead NiceR candidate):		
High-level data readout from Phase 1	GBS Phase 2: Outcome of comparative efficacy analysis	 U.S. ConfideS (Kidney tx) Phase 3 BLA submission
Long-term follow-up (Kidney tx): 5-year data readout	Genethon Crigler-Najjar Phase 1/2: Initiate clinical study with imitidase prior to GNT-0003	 Anti-GBM disease Phase 3: Complete enrolment
GBS Phase 2: First data readout	HNSA-5487 (Lead NiceR candidate): Further analysis around endpoints to be completed in 2024 incl. lead indication	
AMR Phase 2: Full data readout	U.S. ConfideS (Kidney tx) Phase 3: Complete randomization	
Sarepta DMD pre-treatment Phase 1b: Commenced clinical study	Sarepta imilifidase in phase 1b in DMD: First high level data read-out from phase 1b	

Hansa Biopharma AB P.O. Box 785 SE-220 07 Lund, Sweden www.hansabiopharma.com



Company Facts

Founded Stock Exchange Headquarters Employees

2007 NASDAQ Stockholm (HNSA) Lund, Sweden 166

Key Executives Peter Nicklin Søren Tulstrup Evan Ballantyne Matthew Shaulis

Hitto Kaufmann

Chairman President & CEO SVP & CFO CCO & U.S. President CSO

Market Data (Q1 2024)

Market Cap 52 Week Range Avg. Daily Turnover Shares Outstanding	USD ~170m (April '24) SEK 20-58 vol. 248k shares 52m
Top 5 Shareholders	(% S/O)
Redmile Group	18.3%
Nexttobe AB	4.1%
Theodor Jeansson	4.1%

Theodor Jeansson	4.1%
Thomas Olausson	3.6%
Avanza Pension	3.4%

Share Price Graph (12M)



Key Financials

SEKm	FY 2023	Q1'23	Q1'24
Revenue	134	24	56
R&D cost	(411)	(93)	(103)
Net loss	(832)	(205)	(219)
Cash & Short investments	732	1,287	541
Operating Cash Flow	(756)	(182)	(189)
Employees	168	159	166

* Unaudited Calender

Apr 18, 2024	Interim Report for January-March 2024
Apr 22, 2024	ABG Road Show, Stockholm
May 14, 2024	Capital One Biotech Disruptors Event, New York City
May 27, 2024	Carnegie Reverse Road Show, Lund
June 11, 2024	ABG Digital Seminar
June 27, 2024	2024 Annual General Meeting
July 18, 2024	Half-year Report January-June 2024
Sept 19, 2024	Pareto Securities' Annual Healthcare Conference, Sthlm
Oct 24, 2024	Interim Report for January-September 2024

Contacts

Klaus Sindahl Head of Investor Relations M: +46(0)709-298 269 klaus.sindahl@hansabiopharma.com

Stephanie Kenney VP Global Corporate Affairs M: +1 (484) 319 2802 stephanie.kennev@hansabiopharma.com

Advance ongoing imlifidase clinical programs in transplantation and autoimmune diseases Achieve approval/usage

- of imlifidase in follow-on indications Broaden our Idefirix® label beyond kidney
- transplantation

- opportunity
 - transplantation (HSCT)


Broad Pipeline in Kidney Transplantation, Autoimmune Conditions and Gene Therapy



Project	Indication	Research/ Preclinical	Phase 1	Phase 2	Phase 3	Marketing Authorization	Marketed	Partner	Next Anticipated Milestone
	EU: Kidney transplantation in highly sensitized patients ^{1,2}								EU: Additional agreements around reimbursement / Post approval study to be completed by 2025
	U.S. "ConfldeS": Kidney transplantation in highly sensitized patients ^{1,2}								Completion of randomization (64 patients) mid 2024
	GOOD-IDES-02: Anti-GBM antibody disease								Complete enrollment (50 patients)
	16-HMedIdes-12: Active Antibody Mediated Rejection (AMR)								Publication in peer-reviewed journal
mlifidase	15-HMedIdeS-09: Guillain-Barré Syndrome (GBS)								Comparative efficacy analysis 2024
Imlif	Investigator-initiated trial in ANCA-associated vasculitis ³								Complete enrollment (10 patients)
	SRP-9001-104: Pre-treatment ahead of gene therapy in Duchenne Muscular Dystrophy (DMD)		Phase 1b					Sarepta Therapeutics	Completion of enrollment
	Pre-treatment ahead of gene therapy in Limb- Girdle Muscular Dystrophy (LGMD)							Sarepta Therapeutics	Preclinical research
	Pre-treatment ahead of gene therapy in Pompe disease							AskBio	Preclinical research
	Pre-treatment ahead of gene therapy in Crigler- Najjar syndrome							Genethon	Commence clinical study
HNSA- 5487	NICE-01 phase 1: HNSA-5487 – Lead candidate from the NiceR program								Further analysis around endpoints from Phase 1 to be completed in 2024 incl. selection of lead indication
Cor		approval study run lel with commercial		² Lora	ults from the Phase 1 study ha nt et al., American Journal of stigator-initiated study by Dr. /	Transplantation and 03+04	studies (Jordan et al., N	ew England Journal of Me	

Our Business Model





Evolution into a fully integrated biopharmaceutical company

